Pacira Pharmaceuticals (PCRX) : 5 days before expiry, shorts in Pacira Pharmaceuticals (PCRX) have reduced from 4,859,114 on Jul 29, 2016, to 4,787,101 on August 15, 2016. On an average, 996,961 shares are traded on the exchange. The outstanding bearish positions are equal to 13.3% of the float. Short sellers have covered -72,013 shares, a reduction of -1.5%, which underlines that they dont expect the stock to fall further from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.
Pacira Pharmaceuticals (NASDAQ:PCRX): The stock opened at $43.44 on Wednesday but the bulls could not build on the opening and the stock topped out at $43.83 for the day. The stock traded down to $39.61 during the day, due to lack of any buying support eventually closed down at $39.86 with a loss of -8.16% for the day. The stock had closed at $43.40 on the previous day. The total traded volume was 1,116,377 shares.
In a related news, The director officer (CEO and Chairman), of Pacira Pharmaceuticals, Inc., Stack David M had unloaded 15,000 shares at $45.32 per share in a transaction on August 15, 2016. The total value of transaction was $679,800. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.